



## Company Profile

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ / TASE: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

RedHill's pipeline currently includes drugs in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.


RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill's experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

## Stock Performance


### NASDAQ: RDHL.US <sup>1</sup>

Last Trade:	9.85
Trade Time:	4:00 PM ET May 26, 2017
Change:	-0.14 ↓ (1.399%)
Volume	33,972



### TASE: RDHL <sup>1</sup>

Last Trade:	349.50
Trade Time:	3:24 PM IT May 28, 2017
Change:	-3.90 ↓ (1.104%)
Volume	57,598



## Press Releases [ View all ]

May 4, 2017

[RedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017](#)

May 3, 2017

[RedHill Biopharma Reports 2017 First Quarter Financial Results](#)

Apr 25, 2017

[RedHill Biopharma to Host First Quarter 2017 Financial Results Conference Call on May 3, 2017](#)

## Events [ View all ]

Jun 19–22, 2017

[BIO International Convention](#)

Sep 10–12, 2017

[Rodman & Renshaw 19th Annual Global Investment Conference](#)

## Financials [ View all ]

[First Quarter Financial Results](#)

Feb 23, 2017

[Annual Report for Foreign Private Issuers \(20-F\)](#)

## RedHill Biopharma Ltd

Investor Relations Department  
21 Haarbaa St  
Tel Aviv 64739  
Israel

[Visit IR website](#)

[Sign-up for email alerts](#)

